论文部分内容阅读
作者报道新抗茵药Ofloxacin(DL8280)对肺结核病人进行实验性治疗。选例标准:19例病人都是慢性空洞性肺结核,并还在排对各种抗结核药物抗药的结核菌。口服DLB280,每日早饭后一次,剂量为300mg,连服6或8个月。每月做痰标本检查,用金胺染色显微镜检查痰菌,在吐温鸡蛋培养基上培养。测定DL8280的血浆浓度并进行胸部X线照片,以便综合判定疗效。结果表明,该药对治疗肺结核病人是有效的。3
The authors report that the new anti-drug Ofloxacin (DL8280) is an experimental treatment of patients with tuberculosis. Selection criteria: 19 patients were chronic hollow tuberculosis, and are still in the row against a variety of anti-tuberculosis drug-resistant Mycobacterium tuberculosis. Oral DLB280, once daily after breakfast, a dose of 300mg, and even served 6 or 8 months. Sputum specimens are inspected monthly, sputum samples are stained with aurein staining microscope and cultured on Tween egg culture medium. Determination of plasma concentrations of DL8280 and chest X-ray, in order to determine the efficacy of comprehensive. The results show that the drug is effective for the treatment of pulmonary tuberculosis patients. 3